Tri-aryl ethane derivatives as pde iv inhibitors
CA 2238875 C · Owner: Merck Frosst Canada Ltd. · Inventors: Blouin, Marc; Hamel, Pierre; Girard, Yves
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention encompasses the novel compound of formula (I) useful in the , treatment of diseases, including asthma by raising the level of cyclic , adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP comprising the use of , compounds of Formula (I).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 11, 1996 and granted September 16, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 11, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 11, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.